TY - JOUR
T1 - Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma
AU - Kuzuya, Teiji
AU - Tsuchiya, Kaoru
AU - Tanaka, Keisuke
AU - Suzuki, Yuichiro
AU - Hoshioka, Takahide
AU - Tamaki, Shinji
AU - Kato, Tomoji
AU - Yasui, Yutaka
AU - Tanaka, Tomohiro
AU - Hosokawa, Takanori
AU - Ueda, Ken
AU - Nakanishi, Hiroyuki
AU - Itakura, Jun
AU - Kurosaki, Masayuki
AU - Asahina, Yasuhiro
AU - Izumi, Namiki
PY - 2010
Y1 - 2010
N2 - We investigated changes in tumor markers before and after sorafenib therapy for advanced hepatocellular carcinoma (HCC). Subjects were 28 patients who began sorafenib therapy. HCC stage was III (n = 5), IVA (n = 10) and IVB (n = 13). AFP, AFP-L3 and PIVKA-II were compared before and at one month after sorafenib administration. While no significant changes were observed for AFP and AFP-L3, PIVKA-II increased significantly following treatment (p<0.001). Similar results were observed for investigation of outcomes based on RECIST criteria (PR, n = 1; SD, n = 18; PD, n = 9), with increases also observed for PR or SD patients. PIVKA-II increased following sorafenib administration regardless of therapeutic effects based on imaging findings. The present results are very interesting from the perspective of the clinical effects of sorafenib.
AB - We investigated changes in tumor markers before and after sorafenib therapy for advanced hepatocellular carcinoma (HCC). Subjects were 28 patients who began sorafenib therapy. HCC stage was III (n = 5), IVA (n = 10) and IVB (n = 13). AFP, AFP-L3 and PIVKA-II were compared before and at one month after sorafenib administration. While no significant changes were observed for AFP and AFP-L3, PIVKA-II increased significantly following treatment (p<0.001). Similar results were observed for investigation of outcomes based on RECIST criteria (PR, n = 1; SD, n = 18; PD, n = 9), with increases also observed for PR or SD patients. PIVKA-II increased following sorafenib administration regardless of therapeutic effects based on imaging findings. The present results are very interesting from the perspective of the clinical effects of sorafenib.
UR - http://www.scopus.com/inward/record.url?scp=77956031253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956031253&partnerID=8YFLogxK
U2 - 10.2957/kanzo.51.403
DO - 10.2957/kanzo.51.403
M3 - Article
AN - SCOPUS:77956031253
SN - 0451-4203
VL - 51
SP - 403
EP - 404
JO - Kanzo/Acta Hepatologica Japonica
JF - Kanzo/Acta Hepatologica Japonica
IS - 7
ER -